AstraZeneca to supply 400 million of potential vaccine to Europe

▴ astrazeneca-supply-400-million-potential-vaccine-europe
Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon

UK Pharma company AstraZeneca Plc has come in a contract with European governments to provide its potential vaccine against the Coronavirus to assist combat the pandemic.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company reportedly said on Saturday, adding that it had been looking to expand the manufacturing of the vaccine, which it said it might provide for no profit during the pandemic. The vaccine remains in clinical trials. If the trial results convince regulators the vaccine is safe and effective, deliveries would be expected to start out by 2020 end.
The deal thus inscribes that Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon.

"This will make sure that hundreds of millions of people in Europe will have access to the present vaccine, in fact, if it works and that we will know that by summer-end," the company's chief executive, Pascal Soriot was quoted as saying to the journalists. He said he has "good hope" that it'll work, supported initial data.
The alliance "will work alongside the European Commission and other countries in Europe to make sure everybody across Europe is provided with the vaccine," he said.
"We have a really self-sufficient supply chain for Europe" with manufacturers lined up within the Netherlands, Germany, Italy, and Italy, among others, he further said.


The vaccines are for all EU member states. The four nations that agreed the deal can pay for the entire amount, which has not been disclosed, and therefore the scheme allows other countries to hitch it under equivalent conditions, a source from the Italian health ministry said.
Apparently, China, Brazil, Japan, and Russia have also shown interest in this vaccine.
It has got the green signal from The British Medicines and Healthcare products regulatory authority (MHRA) kick start the phase III clinical trial of the vaccine after studies suggest sufficient efficacy and safety, Soriot reportedly said.
At a gathering of EU Health Ministers on Friday, IVA apparently agreed to merge its activities with those of the EU Commission, Germany's Health Ministry said.
It has agreed on the manufacturing of manufacturing 2 billion doses of the vaccine to serve its target beneficiaries along with two Bill Gates-backed ventures and a $1.2 billion agreement with the United States government.
The deal will add an extra 100 million doses to the two billion already committed by the group, AstraZeneca said.
There are not any approved vaccines or treatments for COVID-19, the highly contagious respiratory disease caused by the novel coronavirus.
"Many countries within the world have already secured vaccines, Europe has not yet. The rapid coordinated action of a gaggle of member states will create added value for all EU citizens during this crisis," Italian Health Minister Roberto Speranza was quoted as saying

Tags : #Coronavirus #Vaccine #Astrazeneca #Europe #China #Brazil #BillGates

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Made in India Medical Devices: What Is Changing in 2026?August 28, 2026
The Future of Indian Hospitals: What Healthcare Leaders Are Preparing ForAugust 28, 2026
Kumaran Hospitals Kilpauk Performs 20-Hour Marathon Surgery to Remove Rare, Complex Mesenteric Tumour in 29-Year-OldAugust 27, 2026
India is producing more health research. The bigger question is: how much of it is reaching patients?August 27, 2026
A Raksha Bandhan Gift Beyond Measure: Brother Donates a Part His Liver to Save Sister’s Five-Month-Old DaughterAugust 27, 2026
Second Opinion Gives Eight-Year-Old Boy A Chance To Keep His Leg & His ChildhoodAugust 27, 2026
Hospital Business Models Are Changing: What Comes Next for Indian Healthcare?August 27, 2026
Hospital Business Models Are Changing: What Comes Next for Indian Healthcare?August 27, 2026
Diagnostics in Inflammatory Myopathies: Electromyography (EMG), Muscle Biopsy, and Antibody ProfilingAugust 27, 2026
Ransomware in Healthcare: What Happens When a Hospital's Systems Go Offline?August 27, 2026
Why Indian Hospitals Are Becoming Prime Targets for CyberattacksAugust 27, 2026
Dragged by Tractor, 21-Year-Old Woman Survives Rare Life-Threatening Trauma at Sarvodaya Hospital, FaridabadAugust 26, 2026
Apollo Teynampet expands footprint into multi-speciality healthcareAugust 26, 2026
A Sister’s Gift of Life: Kidney Donation Ahead of Raksha BandhanAugust 26, 2026
Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Beyond Basic Baby Care: Addressing the Monsoon Surge in Infant Skin Concerns with Salve’s Littloo RangeAugust 25, 2026
100+ Bengaluru Clinics Use QR678® as Indian Hair Regeneration Platform Adds New Patent and Expands GloballyAugust 25, 2026
Healthcare Innovation in India: Real Stories That Are Reshaping the Future of MedicineAugust 25, 2026
Generative AI in Indian Hospitals: Where It Is Actually Making a Difference in 2026August 25, 2026